Sage Journals: Discover world-class research

Abstract

The feasibility and relevance of screening a library of raw actinomycete extracts (ECUM library) for the identification of antituberculosis activities was assessed on 11,088 extracts using a multiple-screening approach. Each extract was first tested at two concentrations against noninfected macrophages as a control, then against Mycobacterium tuberculosis growing in broth medium as well as infecting murine macrophages. The screening results indicated a library of good quality with an apparent low proportion of cytotoxic extracts. A correlation was found between both bacterial assays, but the intracellular assay showed limitations due to low rates of cell survival. Several extracts of interest were highlighted by this multiple screening. A focus on the strain producing the two most effective revealed similarities with known producers of active molecules, suggesting the possibility of selecting relevant extracts using this strategy.

Keywords

natural extracts tuberculosis high-content screening actinomycetes

Introduction

Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis (Mtb) and commonly affecting the lungs. Despite the existence of a vaccine, diagnostic tools, and an effective chemotherapy, TB still remains one of the deadliest infectious diseases in the world, with 1.5 million deaths and 9 million new infections reported in 2014.¹ Thanks to the efforts deployed by pharmaceutical companies and academics during the past 15 years, new chemical entities have started to be available for the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains—namely, bedaquiline² and delamanid.³ Both drugs have received conditional regulatory approval for the treatment of MDR infections. However, the high capacity of Mtb to escape drug treatment by acquiring genomic mutations urges us to use these drugs with the utmost precaution. The recent notification of clinical isolates already displaying resistance to bedaquiline⁴ or both bedaquiline and delamanid⁵ is particularly concerning and prompts us to continue our search for new effective drugs. In this context, the characterization of yet unexplored sources of chemical entities is of primary interest.

Nature is a source of unique chemical structures and diversity, and has been a source of medicinal products for thousands of years.⁶ Since the 1940s, actinomycetes’ secondary metabolites, as well as their associated derivatives, have played a major role in the development of anti-TB therapy. This is best exemplified by streptomycin, an extremely potent aminoglycoside targeting protein synthesis in Mtb. Streptomycin was the first clinical drug available against TB^7,8 and is still widely used nowadays for the treatment of drug-resistant TB infections. Similarly, rifampicin was obtained by chemical modifications of rifamycin B, a natural product of the rifamycin family.⁹ Rifampicin is one of the most important drugs of first-line therapy against TB, along with isoniazid. Its sterilizing ability makes it an essential component, as it helps to reduce the treatment duration and the relapse rate.^10,11 Both streptomycin and rifampicin are part of the list of essential medicines as defined by the World Health Organization (WHO),¹² highlighting their value and importance as antibiotics. In addition, many other natural products or derivatives displaying growth inhibition against Mtb are regularly reported in the literature,¹³ proving the value of natural products for the field of anti-TB drugs.

More natural products are yet to be discovered, and the entry into the genomic era has led to a new wave of interest in their use for drug discovery.¹⁴ In South Korea, the Center for Nutraceutical and Pharmaceutical Material (CNPM, www.cnpm.re.kr) in Myongji University collected microorganisms from various geographical regions displaying unusual or extreme climate, with the aim to isolate distinct actinomycete species. Isolated microorganisms with actinomycete-like morphologies were cultivated in the rich, glucose-soybean-starch (GSS; Suppl. Table S1) medium and cryopreserved for maintenance ( Fig. 1A ). For the variety of secondary metabolites, each actinomycete was cultivated in three different media, and extracts were prepared from mycelium cultures and supernatant using different organic solvents, to yield a library referred to as the Extract Collection of Useful Microorganisms (ECUM; http://www.ecum.or.kr). Here, we report our findings regarding the screening of a subset of this library in three different assay systems: against noninfected macrophages, against Mtb replicating in broth medium, and Mtb replicating in macrophages. Our aim was to assess the technical feasibility and relevance of such multiple screenings before undertaking the screening of the entire library.

Figure 1.

(A) Scheme presenting the different steps followed for the preparation of the Extract Collection of Useful Microorganisms (ECUM) library. (B) Overall scheme for the multiple screening. In black, steps related to the extracellular assay, yielding as readout relative fluorescence units (RFU). In white, steps related to the cytotoxicity assay, yielding as readout a percentage of cell survival. In gray, steps related to the intracellular assay, yielding as readout after image analysis a number of cells, an infected surface (expressed in pixels), and a ratio of infected cells.

Materials and Methods

Reagents

DMSO, rifampicin and methanol were from Sigma-Aldrich (Yongin, South Korea). Rifampicin stock solutions were prepared in DMSO at 100 µg/mL and stored at −20 °C. Mycobacteria were cultured in 7H9 broth (Difco; Middlebrook, BD Biosciences, Seoul, South Korea) supplemented with 0.05% Tween 80 (Sigma-Aldrich), 0.2% glycerol (Invitrogen, Thermo Fisher Scientific, Seoul, South Korea), 10% OADC (Middlebrook), and 50 µg/mL hygromycin B (Gibco, Thermo Fisher Scientific, Seoul, South Korea), referred to as 7H9-Tw-Gly medium. Raw264.7 murine macrophages were cultured in RPMI 1640 medium without phenol red (Welgene, Gyeongsan, South Korea, South Korea), supplemented with 10% fetal bovine serum (FBS; Gibco), and referred to as RPMI-FBS medium. Phosphate-buffered saline (PBS), free of calcium and magnesium, was from Welgene.

Extract Preparation

After fermentation of each actinomycete strain, the supernatant and cell pellet were separated by centrifugation at 13,000 rpm for 20 min. One volume of ethyl acetate was added to one volume of supernatant and the mixture vigorously mixed for 20 min. After decantation, the ethyl acetate and water layers were separated and dried under vacuum to afford the crude ethyl acetate and water extracts, respectively. For the cell pellet, metabolites were extracted by addition of methanol (1:1, w/w) and incubation at room temperature for 12 h with mild shaking. The methanol phase was separated from the cell pellet by centrifugation at 13,000 rpm for 20 min and dried under vacuum to afford the methanol extract.

Assay Plate Preparation

Dried extracts (330 µg for water and methanol extractions; 20 µg for ethyl acetate extraction) were delivered in 384-well polypropylene plates (Nunc, Thermo Fisher Scientific, Seoul, South Korea) and resuspended in 20 µL methanol. Sealed plates were left overnight at room temperature with mild shaking to ensure complete solubilization. DMSO (80 µL) was added to generate the mother plates. Five sets of daughter plates were prepared by transferring 15 µL of the mother plate into 15 µL of DMSO. All plates were sealed and stored at −20 °C until further use. On the day of the screening, a full set of daughter plates was thawed at room temperature, and 2 µL was transferred into 18 µL of PBS to generate the intermediate plates. Assay plates were prepared by transferring 5 µL (1000×) or 0.5 µL (10,000×) of the intermediate plate into sterile 384-well plates adapted for confocal microscopy (781091; Greiner Bio-One, Han Sung Sci, Anyang, South Korea). For positive and negative controls, 0.5 µL of stock solutions (100 µg/mL rifampicin and 100% DMSO, respectively) was dispensed in the assay plates. In each plate, 16 wells were dedicated to the positive control and 16 for the negative control. Where required, 4.5 µL PBS was added prior to extract dispensing (control wells and 10,000× dilution).

Extracellular Assay

Mycobacterium tuberculosis strain H37Rv (ATCC 27294) was transformed with the Ms6-based integrative plasmid pNIP48, harboring a green fluorescent protein (GFP) gene from Aequorea victoria under the control of the pBlaF promoter from Mycobacterium fortuitum.¹⁵ The plasmid confers resistance to hygromycin. The resulting strain, Mtb H37Rv-GFP, was propagated at 37 °C in 7H9-Tw-gly medium, washed with PBS, aliquoted, and stored at −80 °C. To obtain dispersed cultures for screening, aliquots were first thawed in 50 mL 7H9-Tw-gly medium and grown for 1 week at 37 °C, 5% CO₂. Cultures were further diluted with fresh medium to an OD_{600 nm} value of 0.1 before incubation for 1 more week at 37 °C, 5% CO₂. Bacteria were harvested at early log-phase by centrifugation at 3000 × g for 10 min, washed twice with PBS, and resuspended in fresh 7H9-Tw-gly to reach an OD_{600 nm} value of 0.01 (10⁶ bacteria/mL). The quality of the bacterial suspension was assessed microscopically before the assay to ensure the absence of clumps. The bacterial suspension was dispensed in assay plates (45 µL/well) using an automated dispenser (Matrix WellMate; Thermo Scientific, Seoul, South Korea). Plates were incubated for 5 days at 37 °C, 5% CO₂ before reading of the fluorescence (excitation, 490 nm; emission, 535 nm) using a microplate reader (Victor 3; PerkinElmer, Seoul, South Korea).

Cytotoxicity and Intracellular Assays

Mtb H37Rv-GFP strain was grown at 37 °C in 7H9-Tw-gly medium as dispersed cultures, harvested at early log-phase by centrifugation at 3000 × g for 10 min, washed twice with PBS, and resuspended in fresh RPMI-FBS to reach an OD_{600 nm} value of 0.02 (2.10⁶ bacteria/mL). In parallel, Raw264.7 macrophages were grown at 37 °C, 5% CO₂ in RPMI-FBS medium up to 70% confluence, detached by mechanical scrapping and collected by centrifugation. The cell pellet was resuspended in fresh RPMI-FBS medium, with the cell concentration determined using a Thoma cell-counting chamber and the concentration of the cell suspension adjusted to 10⁶ cells/mL. One volume of cell suspension was mixed with one volume of bacterial suspension to reach a multiplicity of infection (MOI) of 2, and the mixture was incubated in Erlenmeyer flasks for 2 h at 37 °C under mild shaking (100 rpm). Infected cells were pelleted, washed with RPMI-FBS, and finally resuspended in RPMI-FBS before dispensing in the assay plate (45 µL/well) using an automated dispenser (Matrix WellMate; Thermo Scientific). For the cytotoxicity assay, using noninfected macrophages, Raw264.7 cells were prepared as described above and the suspension adjusted at 5 × 10⁵ cells/mL in RPMI-FBS prior to dispensing (45 µL/well). Plates were incubated for 5 days at 37 °C, 5% CO₂. At the end of the incubation period, cell nuclei were stained using Hoechst 33342 at a final concentration of 2.5 µg/mL for 30 min at 37 °C, 5% CO₂. Plates were sealed and imaged using an automated fluorescence microscope (Operetta; PerkinElmer) equipped with a 10× objective (0.4 NA) and configured for reading in the blue (excitation, 405 nm; emission, 450 nm) and the green (excitation, 488 nm; emission, 520 nm) channels. Three fields were imaged per well, and pictures were analyzed using an in-house software that counted the number of nuclei in the well using the blue channel and determining the position and area of the bacteria using the green channel. The number of cells was determined based on the nuclei population, segmented using an in-house seed growth algorithm.¹⁶ In the case of the cytotoxicity assay, an additional plate without extract was also prepared, centrifuged, and imaged on day 0 to obtain the average number of cells present in the well after plating. Bacteria were detected using a classification method based on a support vector machine algorithm, allowing precise segmentation of the pixels positive for a GFP signal versus background signals.¹⁷ A cell was considered infected if at least two contiguous pixels of bacteria were found within their cytoplasm. The ratio of infected cells was calculated by dividing the number of infected cells by the total number of cells. Data obtained for each field were averaged to give the value per well.

Data Analysis and Normalization

Values obtained for the positive and negative controls were used for data normalization and assay quality. Values obtained from the 66 plates of the same assay were considered to calculate $P_{a v g}$ and P_{SD, avg}, as well as N_avg and N_{SD, avg}, the average and standard deviation of the positive and negative controls, respectively. The assay quality was evaluated using the RFU values for the extracellular assay and the ratio of infected cells for the intracellular assay. The Z′ factor was calculated as follows¹⁸:

Z^{'} = 1 - \frac{3 P_{S D, a v g} + 3 N_{S D, a v g}}{| P_{a v g} - N_{a v g} |} .

A Z′ value above 0.5 was considered representative of a very robust assay, and between 0.2 and 0.5 was considered a robust assay. For the extracellular assay, the percentage of growth inhibition (or percentage of inhibition) was calculated using the RFU value as follows:

\begin{array}{l} % growth inhibition = % inhibition (RFU) \\ = (1 - \frac{RFU - P_{a v g}}{N_{a v g} - P_{a v g}}) \times 100 \end{array}

For the cytotoxicity assay, the percentage of viability was calculated as follows, using C, the number of cells in the well, and P_avg, the average number of cells found in the control wells (1% DMSO):

% viability = (\frac{C}{P_{a v g}}) \times 100 .

An extract was considered cytotoxic if the number of cells counted after 5 days was lower than the average number of cells counted after plating at day 0, which corresponded to 40% cell survival in our conditions. Extracts presenting 40% to 80% cell survival where considered either cytostatic or partially cytotoxic. For the infected macrophage assays, the percentage of cell survival was determined using the cell number $C$ and the values found for the controls as follows:

% cell survival = (\frac{C - N_{a v g}}{P_{a v g} - N_{a v g}}) \times 100 .

In this case, the percentage of cell survival can be a negative number, as the number of cells determined in the well in the presence of extract (C) can be lower than the number of cells found in the negative control (DMSO-treated infected cells, N_avg). This is particularly true in the case of cytotoxic/cytostatic extracts. The percentage of infected surface was determined using the infected surface S (expressed in number of pixels) as follows:

% infected surface = (1 - \frac{S - P_{a v g}}{N_{a v g} - P_{a v g}}) \times 100 .

Finally, the percentage of inhibition, calculated based on the percentage of infected surface or the ratio of infected cells, was obtained using the following formulas:

\begin{array}{l} % inhibition (Infected surface) = \\ 100 - % infected surface . \end{array}

\begin{array}{l} % inhibition (Ratio of infected cells) = \\ 100 - (Ratio of infected cells \times 100) . \end{array}

Normalization, visualization, and extract selection were performed using the Spotfire software (Tibco, Palo Alto, CA). Relative frequency distributions and curve fitting were performed using the Prism software (GraphPad Software, La Jolla, CA). Statistical differences were calculated by Prism software as two-tailed p values.

DNA Purification and 16S Ribosomal RNA Sequencing

Selected microorganisms’ genomic DNA was extracted with the CoreBio genomic DNA isolation kit (CoreBio, Seoul, South Korea), following the recommended protocol. The 16S ribosomal DNA (rDNA) was amplified and sequenced using the universal primers: 27F (forward), 5′-AGAGTTTGATCATGGCTCAG-3′, and 1492R (reverse), 5′-AAGGAGGTGATCCARCCGCA-3′. The sequence was aligned with the closest Streptomyces strains in BLAST using CLUSTAL X,¹⁹ and the phylogenic tree was constructed by the neighbor-joining method, using MEGA6.0 software (MEGA, Tempe, AZ).²⁰ The topology of the phylogenic tree was calculated by 1000 bootstrap replications.²¹

Results

Extract Reformatting

A subset of 11,088 extracts was taken from the complete ECUM library. They originated from 1344 distinct strains, chosen according to their morphological and physiological resemblance to actinomycete strains. To increase the variety of secondary metabolites obtained from each strain, different culture media were used. Three-fourths of the selected strains (1008 strains, 75%) were grown in three different media (GSS, rich medium; BN, Bennett’s regular medium; DYC, poor medium; see Suppl. Table S1 for medium composition), and natural extracts were obtained by extraction with three different solvents (W, water; M, methanol; E, ethyl acetate). Within the remaining strains, some only grew in BN medium (112 strains, 8%), while others were not cultivable in BN medium (224 strains, 17%). Extracts were serially diluted (see Materials and Methods section) to generate two sets of assay plates with final dilutions of 1000× and 10,000× in raw extracts ( Fig. 1B ). For the 1000× set, final concentrations of raw extracts were between 16.5 µg/mL (water, methanol) and 1 µg/mL (ethyl acetate), while concentrations of methanol and DMSO in the assay plates were 0.1% and 1%, respectively. Prior to the screening, we confirmed that such solvent concentrations did not affect bacterial replication or macrophage survival (Suppl. Fig. S1). The screening was performed using naive, noninfected macrophages (cytotoxicity assay), as well as two distinct, validated phenotypic assays based on a fluorescent Mtb H37Rv strain, H37Rv-GFP,^15,22,23 replicating in (1) broth medium, referred to as an extracellular assay, or (2) Raw264.7 murine macrophages, referred to as an intracellular assay ( Fig. 1B ).

Cytotoxicity Assay

Each extract was first tested at both concentrations against noninfected macrophages to identify and quantify the extent of cytotoxic effects within this subset of the library. As shown in Figure 2A , most of the extracts were not cytotoxic or cytostatic for the cells. Indeed, at the 10,000× and 1000× dilution, 98.4% and 84.7% of the extracts displayed above 80% of viability, respectively. As expected, when the extracts were used at higher concentrations (1000×), more cytotoxicity was observed, as indicated by the increased proportion of extracts presenting less than 40% of viability ( Fig. 2A , insert). Correlating the results obtained at both concentrations indicated that most of the extracts were not cytotoxic at both dilutions ( Fig. 2B ). A small proportion was cytotoxic at both dilutions (1.0%) or only at the 1000× dilution (5.4%). The number of extracts with toxicity at only the 10,000× dilution was negligible (1 of 11,088). Counter-checking the pictures taken from the well, some extracts appeared to have a high fluorescence background, but this was without an impact on the detection of the cells due to their much higher fluorescence intensity. Altogether, these results showed that a low proportion of extracts was altering the cell viability, suggesting that this subset of the library was suitable to carry out a phenotypic assay using infected host macrophages.

Figure 2.

(A) Relative frequency of the percentage of viability obtained during the cytotoxicity assay for each dilution. Box: Left part of the graph only, plotted with a different scale on the y-axis to better display the values. The frequency distributions were calculated using Prism software, using a bin width of 5 (24 bins). (B) Two-dimensional plot of the results of the cytotoxicity assay. Extracts are plotted using their percentage of viability obtained at each dilution. Extracts below 40% and 80% of viability (dotted lines) were considered cytotoxic and cytostatic/partially cytotoxic, respectively. Number of extracts falling in relevant subparts of the graph, as delineated by the viability thresholds, is indicated in italics.

Extracellular Assay

The ability of the extracts to prevent Mtb replication in broth medium was assessed by monitoring the fluorescence (RFU) remaining in the well after 5 days of incubation in the presence of the extracts. For each set, 1000× and 10,000×, we confirmed that the distribution frequency of RFU values followed a Gaussian distribution (R² > 0.99), centered on 10,300 and 10,600, respectively ( Fig. 3A ). DMSO (1%) and rifampicin (1 µg/mL) were used as negative and positive controls, respectively. The average Z′ value for the whole extracellular screening was 0.72 (66 plates; min. Z′: 0.41; max. Z′: 0.85; Suppl. Fig. S2A). All RFU values obtained were further normalized using the average values of the positive and negative controls. A threshold of 50% of growth inhibition was chosen, corresponding to an RFU value of 7550. At this threshold, a total of 254 extracts (2.3%) were selectable: 232 extracts (2.1%) displayed an activity at 1000× dilution, while 40 (0.36%) were active at 10,000× dilutions. Among these, 18 (0.16%) were active at both 1000× and 10,000× dilutions ( Fig. 3B ) and were considered the most relevant. Strikingly, among the media used for the growth of the strains producing these 18 extracts, the rich medium (GSS) was overrepresented (94%), while the three solvents used for extraction were more equally found ( Fig. 3C ). It is worth noting that 22 extracts were active at the 10,000× dilution but inactive at the 1000× dilution, an unexpected result. While this remains to be elucidated, the absence of activity at the 1000× dilution for these extracts may be due to interactions with the 7H9-Tw-gly medium when used at the highest concentration (micellization or precipitation). Among the 18 selected extracts, 5 were among the extracts found cytotoxic at both dilutions in the noninfected macrophage assay and were thus rejected. However, three strains were identified in duplicate within this list, strengthening their relevance. A total of 13 extracts and 10 unique strains were finally selected at the end of this extracellular screening campaign ( Table 1 ).

Figure 3.

(A) Relative frequency of the relative fluorescent unit (RFU) values obtained during the extracellular screening for each dilution. Box: Left part of the graph only, plotted with a different scale on the y-axis to better display the values. The frequency distributions were calculated using Prism software, using a bin width of 500 (23 bins). Distributions were fitted using a Gaussian distribution equation (1000×, R² = 0.9975; 10,000×, R² = 0.9941). (B) Two-dimensional plot of the results of the extracellular screening. Extracts are plotted using their normalized RFU values (% growth inhibition) obtained at each dilution. Extracts above the 50% inhibition threshold (dotted lines) for both dilutions are indicated as black, open circles. Number of extracts falling in each subpart of the graph, as delineated by the 50% inhibition thresholds, are indicated in italics. (C) Culture medium (top) and extraction solvent (bottom) conditions for the 18 selected extracts. Number of extracts falling in each group is indicated, as well as the corresponding percentage. BN, Bennett’s regular medium; E, ethyl acetate; GSS, glucose-soybean-starch; M, methanol; W, water.

Table 1.

Extracts Displaying More Than 50% Growth Inhibition at Both 1000× and 10,000× Dilutions for the Extracellular Assay.

Strain	Media^a	Solvent	% Inhibition (RFU)		Viability (%)^b
Strain	Media^a	Solvent	1000×	10,000×	1000×	10,000×
MJU3653	GSS	W	74	64	109	106
MJU3667	GSS	M	67	63	102	106
	GSS	W	61	65	97	105
MJU3668	GSS	M	76	50	14	84
MJU3669	GSS	W	69	63	105	105
MJU3682	GSS	E	55	52	107	106
MJU3683	GSS	E	60	59	106	110
	GSS	W	66	58	89	107
MJU3684	GSS	E	70	53	108	111
	GSS	W	72	63	14	102
MJU3686	GSS	E	59	58	104	104
MJU3702	GSS	M	71	67	51	102
MJU4213	BN	W	80	83	78	97

BN, Bennett’s regular medium; E, ethyl acetate; GSS, glucose-soybean-starch; M, methanol; RFU, relative fluorescent units; W, water.

See Supplemental Table S1 for media composition.

Percentages of viability obtained in the cytotoxicity assay.

Intracellular Assay

The presence of extracts displaying an ability to inhibit bacterial replication in host macrophages was also investigated within this subset of the ECUM library. Indeed, Mtb is known to display a metabolic switch while infecting macrophages, leading to different susceptibilities toward antibiotic treatments.^24,25 It was then interesting to assess, in parallel to the extracellular assay, whether some extracts would be selected as well in macrophages or be specific for one assay or the other. A robust and already validated high-content screening (HCS) approach was used (see Materials and Methods section and Fig. 1B ).^15,26 The infection ratio parameter, as it takes into account both the cellular and bacterial populations, was used to determine the assay quality. The frequency distribution for the 1000× dilution followed a normal distribution (R² > 0.99). In the case of the 10,000× dilution, however, a high number of extracts displayed a low to moderate activity on the ratio of infected cells, and the distribution was better fitted by a sum of two Gaussians (R² > 0.99) rather than a single Gaussian (R² = 0.90) (Suppl. Fig. S3). Nevertheless, the average Z′ value for the whole intracellular screening was 0.77 (66 plates; min. Z′: 0.55; max. Z′: 0.92; Suppl. Fig. S2B).

This large amount of extracts displaying a small reduction of infection ratio at 10,000× led us to investigate the cell number and the infected surface individually to better understand the fate of the cell and the bacteria. Each parameter was normalized based on the positive and negative controls (1 µg/mL rifampicin and 1% DMSO, respectively), and Gaussian distributions were confirmed, with R² > 0.98 ( Fig. 4A , B ). The high frequency of low cell survival was striking, with more than 90% of the extracts displaying less than 10% cell survival for both dilutions ( Fig. 4A ). This result contrasted significantly with the near absence of cytotoxicity observed on noninfected macrophages ( Fig. 2A ). The low rates of cell survival observed at both dilutions in the intracellular assay may be due to cytostaticity, without visible consequences in the cytotoxicity assay but detrimental in the infected macrophage assay due to its higher stringency. Considering the low number of cells remaining in the well, we reasoned that the infection ratio would not be appropriate as a readout of the extract potency and decided to use the cell survival and the infected surface. Of importance, the infected surface, quantifying the area of bacteria in the well, was well adapted to quantify the effect of the extract on the bacterial replication. When these two parameters were plotted together, a subpopulation of extracts displaying more than 40% of cell survival and less than 50% of infected surface was revealed for each dilution ( Fig. 4C ). A total of 88 extracts (0.8%) were selectable using these criteria (50 were selectable at 1000×, 29 at 10,000×, and 9 at both dilutions). However, counter-checking the pictures taken from the corresponding wells revealed that all of these extracts were actually artifacts with high fluorescence background, either due to the extract itself (confirmed with the cytotoxicity assay) or a technical issue during the acquisition ( Fig. 4D ). This result was quite disappointing, but it is worth noting here that, from all the extracts classified as artifacts, none belonged to the list of extracts selected from the extracellular assay.

Figure 4.

Relative frequency distributions for the intracellular screening. (A) Percentage of cell survival. The bin width used was 15 (153 bins total, 14 displayed). Box: Right part of the graph only, plotted with a different scale on the y-axis to better display the values. Distributions were fitted using a Gaussian distribution equation (R² > 0.999). (B) Percentage of infected surface. The bin width used was 15 (104 bins total, 14 displayed). Distributions were fitted using a Gaussian distribution equation (1000×, R² = 0.9894; 10,000×, R² = 0.9883). (C) Two-dimensional plot of the results of the intracellular screening. Extract are plotted using the normalized infected surface (y-axis) and the normalized cell survival (x-axis) obtained at each dilution. The 50% inhibition thresholds are indicated as dotted lines. (D) Representative picture of extracts designated as artifacts. Top left: Extract grown in DYC medium, extracted with water, and screened at a 1000× dilution. Top right: Extract grown in glucose-soybean-starch (GSS) medium, extracted with ethyl acetate, and screened at a 1000× dilution. Bottom left: Extract grown in Bennett’s regular (BN) medium, extracted with water, and screened at a 10,000× dilution. Bottom right: Extract grown in GSS medium, extracted with methanol, and screened at a 10,000× dilution. Scale bar: 200 µm.

Correlation between Both Assays

Despite the lack of potent extracts obtained using these criteria from the intracellular assay, we were interested in investigating how the results were correlated between both bacterial assays. Percentages of inhibition were compared in the case of the 18 extracts selected through the extracellular assay, before removal of the cytotoxic extracts, to keep more information (Suppl. Table S2). It was interesting to see that, for some of these extracts, they were also successful in reducing the infected surface by more than 50% in macrophages without significant cytotoxicity against the noninfected cells but were not selectable in the intracellular assay due to a low rate of cell survival. In this case, the higher stringency of the infected macrophage assay may have masked the desired antibacterial activity. When the percentage of inhibition calculated based on the infected surface (intracellular assay) was plotted against the percentage of growth inhibition (extracellular assay), a significant correlation was obtained between both parameters (R² = 0.39, p < 0.001; Suppl. Fig. S4A). This indicated that the capacity of the extract to inhibit bacterial replication was shared between both assays. As expected, the Pearson correlation coefficient was found to be positive, indicating that a decreased infected surface was correlated with a decreased bacterial growth. While additional experiments are required to confirm this correlation (the assays were conducted only once here), it was comforting to observe such results. Regarding the other parameters, as a very low rate of cell survival was obtained for the 18 extracts (<10%), it was not considered relevant to interpret the results of their correlation with the bacterial growth (Suppl. Fig. S4B,C).

In light of these results and with the wish to extract more data from the intracellular screening, we decided to reevaluate the presence of active extracts focusing only on the infected surface parameter, without consideration for cell survival. By doing so, we drastically increased the number of selectable extracts at 50% inhibition (4718) and thus had to determine a better threshold for the selection of relevant extracts. Using the distribution frequency of the percentage of inhibition, we estimated that a threshold above 70% would allow the selection of relevant extracts with a limited rate of false positives, as this corresponds to more than 1.5 times the standard deviation of the distribution for both dilutions (Suppl. Fig. S4D). From the 415 extracts selectable at this threshold, we only focused on those active at both dilutions (19 extracts). Removing the artifacts yielded a final list of 11 extracts, as summarized in Table 2 . Importantly, two extracts selected here were from the same strain (MJU3671), reinforcing their relevance. In addition, one of these extracts was also highlighted by the extracellular screening (Suppl. Table S2, entry 8). Despite the low viability rate associated with these two extracts, they presented the highest activity in both assays, which led us to investigate the strain MJU3671, producing these extracts in more detail.

Table 2.

Extracts Displaying More Than 70% Inhibition of Infected Surface at Both 1000× and 10,000× Dilutions for the Intracellular Assay.

Strain	Media^a	Solvent	% Inhibition (Infected Surface)		% Inhibition (RFU)		Viability (%)^b
Strain	Media^a	Solvent	1000×	10,000×	1000×	10,000×	1000×	10,000×
MJU3671	GSS	E	103	80	94	72	3	13
	GSS	M	75	71	84	8	4	16
MJU4055	BN	W	70	71	−9	−13	103	99
MJU4090	GSS	M	75	77	9	6	102	98
MJU4163	GSS	M	72	76	82	−3	99	103
MJU4171	GSS	E	73	70	9	−3	67	101
MJU4175	GSS	M	79	70	12	12	103	101
MJU4453	BN	M	71	78	6	−1	104	104
MJU4471	BN	M	70	72	13	−6	104	103
MJU4498	GSS	M	71	71	8	0	53	88
MJU4506	DYC	M	75	71	−1	−8	95	96

BN, Bennett’s regular medium; E, ethyl acetate; GSS, glucose-soybean-starch; M, methanol; RFU, relative fluorescent units; W, water.

See Supplemental Table S1 for media composition.

Percentages of viability obtained in the cytotoxicity assay.

A Focus on the Strain MJU3671

This strain was isolated from a soil sample taken in Ham-Bak-Mountain, South Korea. The 16S rRNA gene of this strain was sequenced, yielding a string of 1426 bp with high similarities for the Streptomyces species. The sequence presented 99% identity with Streptomyces costaricanicus (NBRC 10077), Streptomyces murinus (NBRC 14802) and Streptomyces misionensis (NBRC 13063), and Streptomyces phaeogriseichromatogenes (NRRL 2834T), its closest neighbor within the phylogenetic tree (Suppl. Fig. S5). S. costaricanicus was described for its antibiotic activities against the fungi Rhizoctonia solani and the oomycete Pythium aphanidermatum.²⁷ S. misionensis is producing misionin, described as an antifungal,²⁸ while S. murinus is known to produce members of the actinomycin complex,²⁹ DNA intercalants with antitumor³⁰ as well as anti-TB activity.³¹ Finally, S. phaeogriseichromatogenes was described as a producer of lankamycin and lankacidin, two antibiotic macrolides produced by Streptomyces species.³² It was thus comforting to identify the MJU3671 strain as a producer of extracts with activities against Mtb as well as significant toxicity against the tumor-derived macrophage cell line used, validating our screening approach.

Discussion

Here, we report the screening of 11,088 natural extracts obtained by solvent extraction of the mycelium and supernatant of actinomycete-like cultures. These extracts were tested as a representative subset of the ECUM library to probe the technical feasibility of a multiple screening against this library. Each extract was screened at two different dilutions, using three distinct assays: noninfected macrophages, bacteria replicating in broth medium, and bacteria replicating in macrophages. At the end of the screening campaign, a total of 24 extracts were selected ( Table 1 and Table 2 ), but only one extract was found active in both bacterial assays, while displaying a high toxicity against the noninfected macrophages. This raw ethanolic extract was obtained from a strain of the Streptomyces genus, highly similar to known antibiotic producers. The results obtained here aid us in the capacity of our multiple-screening assay to unravel anti-TB activity within complex natural extracts. Of particular interest here was the very low rates of cell survival observed in the intracellular assay, despite an apparent absence of dramatic viability loss against noninfected cells. While this needs to be investigated further, the higher stringency of this assay may be the reason for this difference. Indeed, an inhibition of the macrophage replication during the first days of incubation, through the presence of antitumor and antiproliferating agents in these extracts, may have only a little impact when using noninfected cells but could be detrimental in the case of infected macrophages, as they rapidly die and release viable bacteria in the supernatant. The use of a nonreplicating cell line, like THP-1 macrophages or non-tumor-derived primary cells, may be a way to palliate this problem and increase the chances to identify valuable fractions from the full library, with the counterparts of increasing the overall cost of the screening. Accordingly to these findings, the protocol of the intracellular assay for the screening of the entire ECUM library (~150,000 extracts) will be revised after evaluating the performance of the assay using different macrophage cells. In addition, the other strains highlighted during this prescreening will be further evaluated to determine their interest in regard to the development of drugs or the identification of pathways of interest for the fight against TB.

Footnotes

Supplementary material for this article is available on the Journal of Biomolecular Screening Web site at

Declaration of Conflicting Interests

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Institut Pasteur Korea is a member of the Institut Pasteur International Network (). This work was supported by the Korean Ministry of Science and International Planning (MSIP, project number NRF-2014K1A4A7A01074643), as well as the Cooperative Research Program for Agriculture Science and Technology Development, Rural Development Administration, Republic of Korea (project number PJ01128901) and the Gyeonggi province, Korea. VD was supported by the French Ministry of Foreign Affairs.

References

World Health Organization (WHO). Global Tuberculosis Report 2015; World Health Organization: Geneva, Switzerland, 2015.

Mahajan

Bedaquiline: First FDA-Approved Tuberculosis Drug in 40 Years. Int. J. Appl. Basic Med. Res. 2013, 3, 1.

Ryan

N. J.

J. H.

Delamanid: First Global Approval. Drugs 2014, 74, 1041–1045.

Somoskovi

Bruderer

Hömke

. A Mutation Associated with Clofazimine and Bedaquiline Cross-Resistance in MDR-TB following Bedaquiline Treatment. Eur. Respir. J. 2015, 45, 554–557.

Hoffmann

Kohl

T. A.

Hofmann-Thiel

. Delamanid and Bedaquiline Resistance in Mycobacterium tuberculosis Ancestral Beijing Genotype Causing Extensively Drug-Resistant Tuberculosis in a Tibetan Refugee. Am. J. Respir. Crit. Care Med. 2016, 193, 337–340.

Borchardt

J. K.

The Beginnings of Drug Therapy: Ancient Mesopotamian Medicine. Drug News Perspect. 2002, 15, 187–192.

Schatz

Bugle

Waksman

S. A.

Streptomycin, a Substance Exhibiting Antibiotic Activity Against Gram-Positive and Gram-Negative Bacteria. Exp. Biol. Med. 1944, 55, 66–69.

Hinshaw

Feldman

In Streptomycin in Treatment of Clinical Tuberculosis: a Preliminary Report, Proceedings of Staff Meetings of the Mayo Clinic, Rochester, Minn. Mayo Clinic: 1945; pp 313–18.

Sensi

History of the Development of Rifampin. Rev. Infect. Dis. 1983, 5(Suppl. 3), S402–S406.

10.

Jindani

Aber

Edwards

. The Early Bactericidal Activity of Drugs in Patients with Pulmonary Tuberculosis. Am. Rev. Respir. Dis. 1980, 121, 939–949.

11.

Jindani

Dore

C. J.

Mitchison

D. A.

Bactericidal and Sterilizing Activities of Antituberculosis Drugs during the First 14 Days. Am. J. Respir. Crit. Care Med. 2003, 167, 1348–1354.

12.

World Health Organization (WHO). WHO Model Lists of Essential Medicines. http://www.who.int/medicines/publications/essentialmedicines/en/

13.

Copp

B. R.

Pearce

A. N.

Natural Product Growth Inhibitors of Mycobacterium tuberculosis. Nat. Prod. Rep. 2007, 24, 278–297.

14.

Harvey

A. L.

Edrada-Ebel

Quinn

R. J.

The Re-emergence of Natural Products for Drug Discovery in the Genomics Era. Nat. Rev. Drug Discov. 2015, 14, 111–129.

15.

Christophe

Ewann

Jeon

H. K.

. High-Content Imaging of Mycobacterium tuberculosis–Infected Macrophages: An In Vitro Model for Tuberculosis Drug Discovery. Fut. Med. Chem. 2010, 2, 1283–1293.

16.

Fenistein

Lenseigne

Christophe

. A Fast, Fully Automated Cell Segmentation Algorithm for High-Throughput and High-Content Screening. Cytometry Part A 2008, 73, 958–964.

17.

Lenseigne

Brodin

Jeon

H. K.

. In Support vector machines for automatic detection of tuberculosis bacteria in confocal microscopy images, 2007 4th IEEE International Symposium on Biomedical Imaging: From Nano to Macro, IEEE: 2007; pp 85–88.

18.

Zhang

J.-H.

Chung

T. D.

Oldenburg

K. R.

A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J. Biomol. Screen. 1999, 4, 67–73.

19.

Thompson

J. D.

Gibson

T. J.

Plewniak

. The CLUSTAL_X Windows Interface: Flexible Strategies for Multiple Sequence Alignment Aided by Quality Analysis Tools. Nucleic Acids Res. 1997, 25, 4876–4882.

20.

Tamura

Dudley

Nei

. MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) Software Version 4.0. Mol. Biol. Evol. 2007, 24, 1596–1599.

21.

Efron

Halloran

Holmes

Bootstrap Confidence Levels for Phylogenetic Trees. Proc. Natl. Acad. Sci. 1996, 93, 13429–13429.

22.

Christophe

Jackson

Jeon

H. K.

. High Content Screening Identifies Decaprenyl-Phosphoribose 2′ Epimerase as a Target for Intracellular Antimycobacterial Inhibitors. PLoS Pathogens 2009, 5, e1000645.

23.

Delorme

Song

O.-R.

Baulard

. Testing Chemical and Genetic Modulators in Mycobacterium tuberculosis Infected Cells Using Phenotypic Assays. In Mycobacteria Protocols; 3rd Edition ed.; Parish

Roberts

D. M.

Eds.; Methods in Molecular Biology; Walker

J. M.

Series Ed.; Humana Press: New York, 2015; Chapter 24, pp. 387–411.

24.

Adams

K. N.

Takaki

Connolly

L. E.

. Drug Tolerance in Replicating Mycobacteria Mediated by a Macrophage-Induced Efflux Mechanism. Cell 2011, 145, 39–53.

25.

Schnappinger

Ehrt

Voskuil

M. I.

. Transcriptional Adaptation of Mycobacterium tuberculosis within Macrophages Insights into the Phagosomal Environment. J. Exp. Med. 2003, 198, 693–704.

26.

Pethe

Bifani

Jang

. Discovery of Q203, a Potent Clinical Candidate for the Treatment of Tuberculosis. Nat. Med. 2013, 19, 1157–1160.

27.

Esnard

Potter

T. L.

Zuckerman

B. M.

Streptomyces costaricanus sp. nov., Isolated from Nematode-Suppressive Soil. Int. J. Syst. Evol. Microbiol. 1995, 45, 775–779.

28.

Cercos

Eilberg

Goyena

. Misionina: antibiotico polienico producido por Streptomyces misionensis n. sp. Rev. Invest. Agricolas 1962, 17, 5–27.

29.

Frommer

Zur Systematik der actinomycin bildenden streptomyceten. Arch. Mikrobiol. 1959, 32, 187–206.

30.

Liu

Chen

Patel

D. J.

Solution Structure of Actinomycin-DNA Complexes: Drug Intercalation at Isolated GC Sites. J. Biomol. NMR 1991, 1, 323–347.

31.

Chen

Song

Wang

. A Marine-Derived Streptomyces sp. MS449 Produces High Yield of Actinomycin X2 and Actinomycin D with Potent Anti-Tuberculosis Activity. Appl. Microbiol. Biotechnol. 2012, 95, 919–927.

32.

Goodfellow

Kumar

Labeda

D. P.

. The Streptomyces violaceusniger Clade: A Home for Streptomycetes with Rugose Ornamented Spores. Antonie van Leeuwenhoek 2007, 92, 173–199.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.42 MB

High-Content Screening of Raw Actinomycete Extracts for the Identification of Antituberculosis Activities

Abstract

Keywords

Introduction

Materials and Methods

Reagents

Extract Preparation

Assay Plate Preparation

Extracellular Assay

Cytotoxicity and Intracellular Assays

Data Analysis and Normalization

DNA Purification and 16S Ribosomal RNA Sequencing

Results

Extract Reformatting

Cytotoxicity Assay

Extracellular Assay

Intracellular Assay

Correlation between Both Assays

A Focus on the Strain MJU3671

Discussion

Footnotes

Declaration of Conflicting Interests

Funding

References

Supplementary Material